Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. - predictors for cardiovascular complications?
- 1 January 1988
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 49 (1) , 111-121
- https://doi.org/10.1016/0049-3848(88)90364-7
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomyThrombosis Research, 1986
- Cardiovascular Complications of Estrogen Therapy for Nondisseminated Prostatic Carcinoma: A Preliminary Report from a Randomized Multicenter StudyScandinavian Journal of Urology and Nephrology, 1986
- Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patientsIntensive Care Medicine, 1984
- Evidence for a rapid inhibitor to tissue plasminogen activator in plasmaThrombosis Research, 1983
- A study of hemostasis in ischemic cerebrovascular disease III. Abnormalities in vascular plasminogen activators, antiactivators and α2-antiplasminThrombosis Research, 1982
- Influence of Age, Sex and Blood Groups on 15 Blood Coagulation Laboratory Variables in a Reference Material Composed of 80 Blood DonorsVox Sanguinis, 1980
- Rapid radioimmunoassay of human fibrinopeptide A — Removal of cross-reacting fibrinogen with bentoniteThrombosis Research, 1980
- HÆMOSTATIC FUNCTION AND CARDIOVASCULAR DEATH: EARLY RESULTS OF A PROSPECTIVE STUDYThe Lancet, 1980
- Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Chromozym TH)Thrombosis Research, 1977
- A NEW METHOD FOR THE QUANTITATIVE DETECTION OF PLATELET AGGREGATES IN PATIENTS WITH ARTERIAL INSUFFICIENCYThe Lancet, 1974